Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,924 recruiting studies in this area right now.
By phase
- Not applicable2,025
- Phase 21,074
- Phase 1791
- Phase 1/Phase 2480
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama157
- Maryland152
- Arizona126
- Florida104
- Massachusetts104
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,924 total
- NCT06465316RecruitingPhase 1
Testing teclistamab with iberdomide for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs (teclistamab and iberdomide) for people with multiple myeloma that has come back or stopped responding to standard treatments. The goal is to see how well this combination works and whether it can help control the disease.
Phoenix, ArizonaAges 18 years+ - NCT06465160RecruitingPhase 1
Study of MNV-201 for low-risk MDS with anemia
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
Jerusalem, IsraelAges 18–100 - NCT06461533Recruiting
A survey of susoctocog alfa for acquired hemophilia A
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
Tokyo, TokyoAges Any age - NCT06465433RecruitingPhase 2
Continued Tafasitamab Treatment for Blood Cancer
This trial allows people with blood cancers who are already benefiting from tafasitamab treatment in another study to keep receiving it. It helps ensure you can continue this therapy without interruption.
GyőrAges 18–99 - NCT06466785RecruitingPhase 3
Study of Efepoetin Alfa for anemia in kidney dialysis patients
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
YerevanAges 18 years+ - NCT06475235RecruitingPhase 1
Pembrolizumab with chemo for new CNS lymphoma
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
Boston, MassachusettsAges 18 years+ - NCT06465953RecruitingPhase 3
Ivosidenib vs azacitidine for IDH1-mutated MDS
This trial tests if the drug ivosidenib alone or azacitidine alone can help people with a specific type of MDS that has an IDH1 mutation. It is for people who have not had strong MDS treatments yet.
Denver, ColoradoAges 18 years+ - NCT06472089Recruiting
Support program for caregivers of stem cell transplant patients
This study tests a program to help caregivers of patients receiving a stem cell transplant (bone marrow transplant) for blood cancer. It aims to reduce stress and provide support during this challenging time.
Birmingham, AlabamaAges 18 years+ - NCT06471738RecruitingPhase 2
Targeted drug combo for untreated follicular lymphoma
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
BeijingAges 18 years+ - NCT06469307Recruiting
Patient advisory board for inclusive cancer research
This study is about forming a community advisory board (a group of patients and researchers) to help make cancer research at Dana-Farber more inclusive and fair. It is not a treatment trial—instead, you would review study materials and give your perspective.
Boston, MassachusettsAges 18 years+ - NCT06461988RecruitingPhase 2
Talquetamab and lenalidomide after stem cell transplant for myeloma
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Palo Alto, CaliforniaAges 18 years+ - NCT06468215Recruiting
Fertility-sparing treatment for early stage 2 endometrial cancer
This study tests a way to treat early-stage endometrial cancer without removing the uterus, so you can still have a chance to carry a pregnancy. It’s for women under 45 with a grade 2 tumor that hasn’t grown into the womb muscle.
Beijing, Beijing MunicipalityAges Up to 45 years - NCT06466395RecruitingPhase 1
Hyper-CVAD plus venetoclax for relapsed pediatric leukemia
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
Houston, TexasAges 2–21 - NCT06472128Recruiting
New digital app for adults with acute myeloid leukemia
This study tests a digital application to help patients with acute myeloid leukemia (AML) during their hospital stay. It may assist with tracking symptoms, education, or communication with care teams.
Boston, MassachusettsAges 18–120 - NCT06476691Enrolling by invitation
Quality of life after bone marrow transplant in young adults
This study looks at how a bone marrow transplant affects the quality of life of young adults. It follows patients who had or will have a transplant at Rigshospitalet in Denmark.
CopenhagenAges 18–29 - NCT06466122RecruitingPhase 2
Pirtobrutinib plus Venetoclax for resistant CLL or SLL
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Columbus, OhioAges 18 years+ - NCT06468943Enrolling by invitationPhase 2
New drug combo for non-GCB diffuse large B-cell lymphoma
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Suzhou, NanjingAges 18 years+ - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT06471296Recruiting
How viruses affect tumors and treatment response
This study looks at tumor samples from people with certain cancers to compare those caused by viruses (like HPV, HIV, or EBV) with those not caused by viruses. The goal is to understand why some tumors respond differently to treatments, which may help improve future treatment approaches.
ParisAges 18–100 - NCT06472830Enrolling by invitation
MGUS and multiple myeloma awareness screening study
This study screens adults aged 40 and older for early signs of MGUS (a benign blood condition) and multiple myeloma (a blood cancer). You'll fill out questionnaires about your health to help with early detection.
Rochester, MinnesotaAges 40 years+ - NCT06472518RecruitingPhase 4
Clot-busting treatment plus blood thinners for severe leg clots
This trial tests whether combining a clot-busting procedure (pharmaco-mechanical thrombolysis) with standard blood thinners works better than blood thinners alone for people with severe, recently formed deep vein clots in the upper leg.
NantesAges 18 years+ - NCT06468111Recruiting
Can therapy dogs help kids during blood draws or dental work?
This study tests if having a gentle therapy dog nearby can help children ages 3 to 12 feel calmer and more comfortable during a blood draw or dental procedure. If your child likes dogs and needs one of these procedures, this might be a good fit.
LleidaAges 3–12 - NCT06474182Recruiting
Apixaban for blood clots in myeloma patients
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
Saint-EtienneAges 18 years+ - NCT02670707RecruitingPhase 3
Vinblastine plus prednisone versus cytarabine alone for LCH
This phase 3 study compares two treatment plans for Langerhans cell histiocytosis (LCH): vinblastine plus prednisone versus cytarabine alone. It aims to find which approach works better and is safer for children and young adults with LCH that needs medicines.
Palo Alto, CaliforniaAges Up to 21 years
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,924 recruiting hematology studies from the U.S. registry right now, out of 7,354 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.